Clinical Trial Update: Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma [Phase 1]

View source ↗

Summary

Phase 1 study of GRN-1201 in HLA-A*02 subjects with resected melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• GRN-1201

Snippet

Sponsor: BrightPath Biotherapeutics | Conditions: Melanoma | Phase 1 | Status: COMPLETED